## BMRN: BioMarin Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 9.9% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($56.82)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio**
- Source: Morningstar | 20251223T020922 | Bullish | Relevance: 100%
- BioMarin has made a $4.8 billion deal to acquire Amicus Therapeutics, expanding its portfolio of rare genetic-disease therapies. This acquisition is expected to supplement BioMarin's deep in-house pipeline and build on its strong position in the rare disease market. The company, which has historically focused on rare genetic diseases, is confident in its profit-generating power despite previous commercialization and R&D expenses.

**2. Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition**
- Source: Finviz | 20251222T221800 | Bullish | Relevance: 100%
- Analysts have become more bullish on BioMarin Pharmaceuticals Inc. (BMRN) following its announced acquisition of Amicus Therapeutics for $4.8 billion. This deal is expected to strengthen BioMarin's position in rare metabolic diseases by adding key therapies like Galafold and Pombiliti + Opfolda, with analysts citing strong strategic fit and potential for boosted sales. The acquisition is projected to be accretive to non-GAAP earnings within 12 months post-closure in Q2 2026.

**3. BioMarin to Acquire Amicus Therapeutics for $4.8 Billion**
- Source: New Jersey Business Magazine | 20251223T211122 | Bullish | Relevance: 100%
- BioMarin Pharmaceutical Inc. announced its definitive agreement to acquire Princeton-based Amicus Therapeutics for $4.8 billion in an all-cash transaction. The acquisition, approved by both companies' boards, is expected to close in Q2 2026, strengthening BioMarin's commercial portfolio with treatments for Fabry and Pompe diseases, and expanding its presence in rare kidney disease research. This merger is anticipated to accelerate BioMarin's revenue growth, diversify its commercial portfolio, and deliver significant shareholder value.

**4. What's Going On With BioMarin Stock On Tuesday?**
- Source: Benzinga | 20251223T180922 | Bullish | Relevance: 100%
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has agreed to acquire Amicus Therapeutics, Inc. (NASDAQ: FOLD) for approximately $4.8 billion, a move expected to accelerate BioMarin's revenue growth and strengthen its financial outlook. Analysts view the acquisition favorably, citing strategic fit and diversification, despite potential competition for Voxzogo. The stock currently shows a bullish setup in the short term, trading above key moving averages, but faces a longer-term bearish trend.

**5. BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $60.00 Price Target at HC Wainwright**
- Source: MarketBeat | 20251222T141016 | Neutral | Relevance: 100%
- HC Wainwright adjusted its price target for BioMarin Pharmaceutical (NASDAQ:BMRN) from $55.00 to $60.00, maintaining a "neutral" rating despite the company missing its recent quarterly EPS and revenue estimates. While the new target suggests a slight downside, the consensus among 25 analysts is a "Moderate Buy" with an average price target of $88.83, significantly higher than the current share price. BioMarin also provided a positive FY2025 EPS guidance, surpassing analyst projections.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | Truist Securiti | $100 | $80 | +25% |
| 2025-12-22 | HC Wainwright & | $60 | $55 | +9% |
| 2025-12-03 | Leerink Partner | $60 | $82 | -27% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | Truist Securiti | main | Buy |
| 2025-12-22 | HC Wainwright & | main | Neutral |
| 2025-12-03 | Leerink Partner | down | Market Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 11.5% (-8.1%)
- Vanguard Group Inc: 9.7% (-2.2%)
- Primecap Management : 7.9% (-3.4%)
- Dodge & Cox Inc.: 7.6% (-2.8%)
- State Street Corpora: 4.6% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +9.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.61 indicates undervaluation relative to growth. Forward P/E 11.5x attractive for 49% earnings growth. Quality metrics strong (margin 17%). Balance sheet: strong liquidity (4.8x), low leverage (D/E 0.26). Analyst sentiment positive (2 raises, avg +17%). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.7B |
| Beta | 0.30 |
| 52W Range | $50.76 - $73.51 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.61 |
| Forward P/E | 11.5 |
| Current P/E | 17.1 |
| YoY Growth | 48.6% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from 0.6% to 9.9% (+9.3% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (9.9% > 6.0%), caution on chasing. MRS_5 at 5.6% confirms short-term momentum alignment. Outperforming sector by 10.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.83), confirming momentum. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 9.93% (CS: 99) | Strong |
| RSI_14 | 69.0 | Neutral |
| MACD Histogram | 0.83 | Bullish |
| vs SMA20 | 1.117x | Above |
| vs SMA50 | 1.134x | Above |
| vs SMA200 | 1.057x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $61.14
- **Stop Loss:** $56.82 (7.1% risk)
- **Target:** $65.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 277
- **Position Value:** $16,935.78
- **Portfolio %:** 16.94%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-19 (Est: $0.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.34 | $0.12 | -64.3% |
| 2025Q2 | $1.03 | $1.44 | +39.4% |
| 2025Q1 | $0.95 | $1.13 | +18.6% |
| 2024Q4 | $0.74 | $0.92 | +24.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*